APA (7th ed.) Citation

A, M. W., I, P., P, F., M, L., P, L., O, S., . . . A, E. (2026). A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use. CNS drugs, 40(8), 1165. https://doi.org/10.1007/s40263-026-01302-y

Chicago Style (17th ed.) Citation

A, Merenlender Wagner, et al. "A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use." CNS Drugs 40, no. 8 (2026): 1165. https://doi.org/10.1007/s40263-026-01302-y.

MLA (9th ed.) Citation

A, Merenlender Wagner, et al. "A Phase 1 Open-Label Study Assessing the Safety and Pharmacokinetics of TV-46000, an Extended-Release Injectable Suspension of Risperidone for Subcutaneous Use." CNS Drugs, vol. 40, no. 8, 2026, p. 1165, https://doi.org/10.1007/s40263-026-01302-y.